Cardinal Health Surges to 184th Most Traded Stock with $473 Million Turnover

On June 12, 2025, Cardinal Health (CAH) experienced a significant surge in trading volume, with a total turnover of $473 million, marking a 42.6% increase from the previous day. This surge positioned Cardinal Health as the 184th most traded stock of the day. The company's stock price also rose by 4.55%, continuing an upward trend that has seen a 4.86% increase over the past two days.

Cardinal Health recently announced a series of strategic initiatives and financial updates that have bolstered investor confidence. The company has raised its fiscal year 2025 non-GAAP diluted EPS guidance to a range of $8.15 to $8.20, reflecting a 9% growth at the midpoint. Additionally, Cardinal Health has established preliminary guidance for fiscal year 2026, projecting non-GAAP diluted EPS to range from $9.10 to $9.30, indicating a 13% growth at the midpoint.

The company has also reiterated its long-term target of achieving a 12% to 14% non-GAAP diluted EPS compound annual growth rate (CAGR) from fiscal year 2026 to 2028. This target is supported by a robust capital allocation framework that includes significant investments in capital expenditures and share repurchases. Cardinal Health plans to invest at least $600 million annually in capital expenditures and expects to repurchase at least $750 million in shares each year over the next three years.

Cardinal Health's strategic priorities include expanding its Pharmaceutical and Specialty Solutions segment, investing in Biopharma Solutions, and enhancing its core pharmaceutical distribution capabilities. The company has launched The Specialty Alliance, a multi-specialty MSO platform that encompasses recent acquisitions and supports approximately 2,200 providers across 28 states. Additionally, Cardinal Health is investing in its Biopharma Solutions, expanding its data and insights platforms to support manufacturer partners and practitioner customers.

In terms of financial updates, Cardinal Health has narrowed its fiscal year 2025 guidance for non-GAAP diluted EPS to a range of $8.15 to $8.20, up from the previous range of $8.05 to $8.15. The company has also raised its guidance for Pharmaceutical and Specialty Solutions segment profit to a range of 12% to 13% growth, and for Other segment profit to a range of 19% to 21% growth. These updates reflect Cardinal Health's commitment to delivering sustainable long-term growth and value creation for its stakeholders.